Reported 18 days ago
Hong Kong Exchanges and Clearing (HKEX) is set to debut the Hang Seng Biotech Index Futures on November 28, aiming to provide a risk management tool for investors in the rapidly growing biopharmaceutical sector. The new contracts will track the performance of the 30 largest Hong Kong-listed Chinese pharmaceutical and medical device companies, as interest from offshore investors surges. This launch underscores HKEX's commitment to enhancing Hong Kong's status as Asia's premier derivatives trading hub.
Source: YAHOO